Secily N Bason-Mitchell, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 28 years
- Graduated 1998
Offices
1 location · Pacific Womens Obstetrics and Gynecology Medical Group Inc · 7 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bason-Mitchell’s office at (415) 379-9794 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A71787 · Current
Licensed to practise in California · since 2000 · expires 2028-03-31 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$6,386
Medicare paid this office $6,386 for 28 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 13 | $1,524 | $95 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $849 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $757 | $47 |
Who their Medicare patients are
28 Original Medicare patients in 2024. Average age 72 · Women 100% · Also on Medicaid 0% · Health risk score 0.54. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
The office billed $20,141, Medicare allowed $8,196 and paid $6,386; for 63 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 28 | 63 | 72 | 0.54 | $20,141 | $6,386 |
| 2023 | 30 | 67 | 71 | 0.53 | $8,624 | $4,083 |
| 2022 | 26 | 74 | 72 | 0.66 | $15,622 | $5,874 |
| 2021 | 12 | 26 | 73 | 0.70 | $2,778 | $1,491 |
| 2020 | 17 | 35 | 72 | 0.51 | $11,033 | $3,172 |
| 2019 | 22 | 49 | 72 | 0.67 | $12,170 | $4,238 |
| 2018 | 14 | 37 | 73 | 0.95 | $3,488 | $1,570 |
| 2017 | 18 | 45 | 69 | 0.73 | $11,623 | $2,071 |
| 2016 | 13 | 31 | 71 | 0.58 | $3,948 | $1,223 |
| 2015 | 17 | 40 | 70 | 0.86 | $5,995 | $2,642 |
| 2014 | 12 | 32 | 72 | 0.69 | $2,388 | $1,214 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 12 | $1,055 | $66 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,039 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 20 | $938 | $47 |
2022: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,014 | $53 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $837 | $46 |
Drugs they prescribed that Part D paid
$24,606
Pharmacies billed $24,606 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 82) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
50 generic and 32 brand-name prescriptions · $24,606 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 20 | $10,768 | $538 |
| Estradiol | 13 | $1,136 | $87 |
Year by year
| 2024 | 82 | 22 | 0% (0) | 39% | $24,606 |
| 2023 | 78 | 23 | 0% (0) | 36% | $20,414 |
| 2022 | 68 | 21 | None | 54% | $21,302 |
| 2021 | 57 | 14 | 0% (0) | 46% | $14,107 |
| 2020 | 60 | 17 | None | 32% | $9,534 |
| 2019 | 70 | 21 | None | 36% | $9,556 |
| 2018 | 42 | None | 0% (0) | 57% | $7,865 |
| 2017 | 61 | 13 | None | 41% | $8,787 |
| 2016 | 91 | 12 | 0% (0) | 44% | $9,471 |
| 2015 | 58 | 12 | None | 47% | $6,281 |
| 2014 | 36 | None | 0% (0) | 56% | $4,749 |
| 2013 | 47 | 11 | 0% (0) | 57% | $5,274 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Estring | 11 | $5,845 | $531 |
2021: 2 drugs
| Premarin | 16 | $7,347 | $459 |
| Dotti | 12 | $752 | $63 |
2017: 1 drug
| Labetalol | 12 | $133 | $11 |
2016: 3 drugs
| Estring | 14 | $4,426 | $316 |
| Premarin | 13 | $2,846 | $219 |
| Escitalopram | 17 | $104 | $6 |
2015: 1 drug
| Estring | 12 | $3,252 | $271 |
2013: 1 drug
| Estring | 11 | $2,293 | $208 |
Money from drug and device companies
$598 in 2025
| 2025 | 12 | 28 | None | $598 |
| 2024 | 14 | 33 | None | $956 |
| 2023 | 11 | 16 | None | $495 |
| 2022 | 11 | 26 | None | $574 |
| 2021 | 5 | 16 | None | $288 |
| 2020 | 2 | 3 | None | $66 |
| 2019 | 6 | 7 | None | $124 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biogen | Zurzuvae | $201 | 9 payments
|
| Astellas Pharma US | Veozah | $74 | 3 payments
|
| Organon | Nexplanon | $53 | 3 payments
|
| Pfizer | Abrysvo | $42 | 2 payments
|
| Millicent US | Intrarosa | $41 | 2 payments
|
| CooperSurgical | Paragard T 380a | $32 | 2 payments
|
See all 28 published payments
| Astellas Pharma US | Meals · 2025-12-15 | Veozah | $33 |
| Exeltis USA | Meals · 2025-12-12 | Slynd | $25 |
| Biogen | Meals · 2025-12-01 | Zurzuvae | $28 |
| Pfizer | Meals · 2025-11-13 | Abrysvo | $22 |
| Biogen | Meals · 2025-11-04 | Zurzuvae | $30 |
| Organon | Meals · 2025-10-21 | Nexplanon | $20 |
| Amgen | Meals · 2025-10-15 | Evenity | $24 |
| Hologic Sales and Service | Meals · 2025-10-04 | Aptima | $23 |
| CooperSurgical | Meals · 2025-10-04 | Paragard T 380a | $17 |
| Mayne Pharma Commercial | Meals · 2025-09-15 | None | $22 |
| Biogen | Meals · 2025-08-09 | Zurzuvae | $26 |
| Mayne Pharma Commercial | Meals · 2025-08-06 | None | $7 |
| Pfizer | Meals · 2025-08-03 | Abrysvo | $20 |
| Biogen | Meals · 2025-06-30 | Zurzuvae | $29 |
| Organon | Meals · 2025-06-17 | Nexplanon | $17 |
| Biogen | Meals · 2025-05-30 | Zurzuvae | $24 |
| Biogen | Meals · 2025-05-30 | Zurzuvae | $1 |
| Millicent US | Meals · 2025-05-13 | Intrarosa | $25 |
| Biogen | Meals · 2025-04-07 | Zurzuvae | $25 |
| Vertex Pharmaceuticals | Meals · 2025-03-27 | Journavx | $31 |
| Meditrina | Meals · 2025-03-19 | None | $21 |
| Astellas Pharma US | Meals · 2025-03-12 | Veozah | $19 |
| Biogen | Education · 2025-02-25 | Zurzuvae | $10 |
| Millicent US | Meals · 2025-02-21 | Femring | $17 |
| Organon | Meals · 2025-02-19 | Nexplanon | $17 |
| Biogen | Meals · 2025-02-18 | Zurzuvae | $29 |
| CooperSurgical | Meals · 2025-02-12 | Paragard T 380a | $15 |
| Astellas Pharma US | Meals · 2025-01-15 | Veozah | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $956
| Astellas Pharma US | None | $255 | 3 payments
|
| Hologic Sales and Service | Acessa Provu System | $196 | 3 payments
|
| Biogen | Zurzuvae | $149 | 7 payments
|
| Millicent US | Femring | $103 | 5 payments
|
| Lilly USA | Jardiance | $44 | 2 payments
|
| Vertex Pharmaceuticals | None | $33 | 1 payment
|
| Sanofi Pasteur | Beyfortus | $31 | 1 payment
|
| Pfizer | Abrysvo | $24 | 1 payment
|
| Evofem Biosciences | None | $22 | 1 payment
|
| Amgen | Evenity | $22 | 1 payment
|
| Minerva Surgical | None | $21 | 1 payment
|
| Mayne Pharma Commercial | None | $21 | 5 payments
|
| Organon | Nexplanon | $20 | 1 payment
|
| Meditrina | None | $17 | 1 payment
|
2023: $495
| Myriad Women's Health | None | $148 | 2 payments
|
| Mayne Pharma Commercial | None | $63 | 2 payments
|
| Shield Therapeutics | Accrufer | $47 | 2 payments
|
| Astellas Pharma US | Veozah | $47 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $46 | 2 payments
|
| Hologic Sales and Service | Aptima | $27 | 1 payment
|
| Organon | Nexplanon | $26 | 1 payment
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Amgen | Evenity | $24 | 1 payment
|
| Minerva Surgical | None | $23 | 1 payment
|
| Evofem Biosciences | Phexxi | $19 | 1 payment
|
2022: $574
| Abbvie | Lo Loestrin Fe | $198 | 9 payments
|
| Hologic | Thinprep 2000 Processor | $63 | 2 payments
|
| Mayne Pharma | None | $58 | 3 payments
|
| TherapeuticsMD | Annovera | $57 | 3 payments
|
| Scynexis | None | $50 | 2 payments
|
| Evofem Biosciences | Phexxi | $41 | 2 payments
|
| Medicem | Dilapan-S | $28 | 1 payment
|
| Sage Therapeutics | Zulresso | $25 | 1 payment
|
| Organon | Nexplanon | $23 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $17 | 1 payment
|
| Myovant Sciences | Myfembree | $14 | 1 payment
|
2021: $288
| Avion Pharmaceuticals | Balcoltra | $94 | 7 payments
|
| AbbVie | Lo Loestrin Fe | $93 | 4 payments
|
| TherapeuticsMD | Annovera | $57 | 3 payments
|
| Ethicon US | Surgicel Nu-Knit | $26 | 1 payment
|
| Organon | None | $18 | 1 payment
|
2020: $66
| AbbVie | Orilissa | $44 | 2 payments
|
| Avion Pharmaceuticals | Balcoltra | $22 | 1 payment
|
2019: $124
| Bayer HealthCare Pharmaceuticals | Kyleena | $36 | 2 payments
|
| AbbVie | Orilissa | $24 | 1 payment
|
| TherapeuticsMD | Bijuva | $19 | 1 payment
|
| Vertical Pharmaceuticals | Divigel | $19 | 1 payment
|
| Avion Pharmaceuticals | Prenate Mini | $14 | 1 payment
|
| Exeltis USA | Slynd | $12 | 1 payment
|
Professional record
- NPI
- 1992872089
- Licence
- CA A71787California A71787: Current · expires 2028-03-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0000X (207VX0000X); Federal specialty code 207VG0400X (207VG0400X)
- Mailing address
- 3838 California St, 316, San Francisco, CA, 94118
- NPI first listed
- 2006-11-30
- NPI last updated
- 2025-09-11
This is when the NPI record was last certified, not a medical board exam.